"It doesn't matter to a patient if it's nanotechnology or not; it matters if it's efficacious and safe."

— Donald Payne, president/CEO of Nanospectra, on the company's nano-scale product in development as a destroyer of tumors, which FDA won't classify as nanomaterials, "Nanoshells for destruction of tumors enter human trials," pp. 1, 8.